Digital Biomarkers Market Research Report Information By Type (Wearable, Mobile Based Applications, Sensors and Others), By Clinical Practice (Diagnostic Digital Biomarkers, Monitoring Digital Biomarkers, Predictive and Prognostic Digital Biomarkers and Others), by End Use (Healthcare Companies, Healthcare Providers, Payers and Others) And By Region (North America, Europe, Asia-Pacific, And The Rest Of The World) –Market Forecast Till 2032

Digital Biomarkers Market Overview

The Digital Biomarkers Market Size valued at USD 3.1 Billion in 2022 and is projected to rise from USD 3.8 Billion in 2023 to USD 19.39 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 22.60% during the forecast period (2023 - 2032). Increased adoption of digital healthcare solutions and growth in the burden of the chronic diseases are the key market drivers improving the growth of market.

Source: The Secondary Research, Primary Research, MRFR Database and Analyst Review

Digital Biomarkers Market Trends

Growing prevalence of the chronic diseases is driving the market growth

Market CAGR for digital biomarkers is being driven by the rising prevalence of chronic diseases. Chronic diseases, like diabetes, cardiovascular diseases, cancer and neurological disorders, have been on the rise globally. Chronic diseases often require long-term management and can be more effectively treated when detected early. Digital biomarkers, derived from continuous monitoring of health data through digital tools, can provide early warning signs and insights into disease progression. This is particularly valuable in managing chronic conditions, as it allows for timely interventions and adjustments in treatment plans.

The prevalence of the chronic diseases has led to a growing interest in personalized medicine approaches. Digital biomarkers play a crucial role in tailoring treatments and the interventions to individual patients based on their unique health data. This customization can lead to better outcomes and improved quality of life for those with chronic conditions. Chronic disease management often involves regular check-ups and monitoring, which can be burdensome for the patients and healthcare systems. Digital biomarkers enable remote patient monitoring, allowing healthcare providers to track health status of patients without the need for frequent in-person visits. This not only improves patient convenience but also reduces healthcare costs. The prevalence of chronic diseases fuels research and development efforts aimed at finding new treatments and therapies. Digital biomarkers are increasingly used in clinical trials and drug development to assess the efficacy and safety of new interventions.

In an era of -data-driven healthcare, digital biomarkers provide a wealth of information that can be analyzed for insights into disease trends, risk factors and treatment effectiveness. This data-driven approach is crucial for optimizing healthcare strategies, resource allocation and public health initiatives related to chronic diseases. Further, the growing prevalence of chronic diseases and the recognition of the importance of digital biomarkers in managing these conditions have attracted investments and spurred innovation in the digital biomarkers market. This, in turn, leads to market growth as more companies and research organizations focus on developing and utilizing digital biomarkers.

In conclusion, the growing prevalence of chronic diseases is a significant driver for the growth of the digital biomarkers market. Digital biomarkers have the potential in revolutionizing the management and treatment of chronic conditions by providing valuable insights and data-driven solutions, making them a critical component of modern healthcare strategies. Thus driving the Digital Biomarkers market revenue.

Digital Biomarkers Market Segment Insights

Digital Biomarkers Type Insights

The Digital Biomarkers Market segmentation, based on type, includes Wearable, Mobile Based Applications, Sensors and Others. The wearable segment dominates the market, with the largest market share of 39.5% in 2022. The wearable medical devices are designed for continuous monitoring of various physiological and behavioral parameters, like heart rate, sleep patterns, activity levels and more. This continuous data collection provides a rich source of information for digital biomarkers, enabling healthcare professionals to gain insights into a patient's health status over time. Further, they are non-invasive, convenient, provide real-time data and are often integrated with the healthcare ecosystem. The mobile-based application is anticipated to witness the second-fastest growth throughout the forecast period.

Digital Biomarkers Clinical Practice Insights

The Digital Biomarkers Market segmentation, based on clinical practice, includes Diagnostic Digital Biomarkers, Monitoring Digital Biomarkers, Predictive and Prognostic Digital Biomarkers and Others. Diagnostic digital biomarkers dominate the market in the segment of clinical practice. These biomarkers are designed to identify specific patterns or abnormalities in digital health data that can serve as indicators of disease or health conditions. Further, it monitors the disease and provides objective and quantifiable data, reducing the reliance on subjective assessments by healthcare professionals. It also provides personalized medication, is integrated with healthcare systems, is efficient and cost-effective and has attained huge investments. Furthermore, the monitoring of digital biomarkers is anticipated to experience the second-fastest growth during the forecast period.

Digital Biomarkers End-Use Insights

The Digital Biomarkers Market segmentation, based on end use, includes Healthcare Companies, Healthcare Providers, Payers and Others. The healthcare companies category dominates the market as it has been working to integrate digital measurements across the spectrum of clinical care and research to ensure connected devices offer a comprehensive view of patient health. Further, the payers segment is anticipated to rise a rapidly throughout the forecast period due to the increasing adoption of new digital biomarkers in insurance firms and the ability of payers to satisfy patient’s needs.

Figure 1: Digital Biomarkers Market, by End Use, 2022 & 2032 (USD Billion)

Source: The Secondary Research, Primary Research, MRFR Database and Analyst Review

Digital Biomarkers Regional Insights

By region, the study gives market insights into North America, Europe, Asia-Pacific and the Rest of the World. The North American Digital Biomarkers market area dominates the market because of the firm presence of leading market participants, increase in investments in research and development and significant product launches, rising approval for smart devices, and enhanced awareness of the digital biomarker effectiveness in the North American region.

Further, the prime countries studied in the market report are The US, Canada, Germany, France, the UK, Italy, Spain, Japan, India, China, Australia, South Korea, and Brazil.

Figure 2: DIGITAL BIOMARKERS MARKET SHARE BY REGION 2022 (USD Billion)

Source: The Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe's Digital Biomarkers market accounts for the second-largest market share because the market is driven by a rising number of chronically ill patients that require real-time monitoring and diagnostics of various diseases and the presence of the advanced healthcare infrastructure in this region. Further, the German Digital Biomarkers market held the largest market share, and the UK Digital Biomarkers market was the fastest-growing market in European region.

The Asia-Pacific Digital Biomarkers Market is anticipated to grow at the rapid CAGR from 2023 to 2032. This is because of the growing chronic disease burden, the presence of an aging population, growing healthcare expenditure and advancements in technologies. Moreover, China’s Digital Biomarkers market held the largest market share, and the Indian Digital Biomarkers market was the fastest-growing market in Asia-Pacific region.

Digital Biomarkers Key Market Players & Competitive Insights

Leading market players are investing hugely in research and development in order to expand their product lines, which will help the Digital Biomarkers market grow even more. Market players are also undertaking a variety of strategic activities to spread their global footprint, with important market developments including mergers and acquisitions, new product launches, contractual agreements, higher investments, and collaboration with other organizations. To spread and survive in a more competitive and rising market climate, the Digital Biomarkers industry must offer cost-effective items.

Manufacturing locally to reduce the operational costs is one of the key business tactics used by the manufacturers in the global Digital Biomarkers industry to benefit clients and grow the market sector. In recent years, the Digital Biomarkers industry has offered some of the most significant advantages to the medicine. Major players in the Digital Biomarkers market, including ActiGraph LLC; AliveCor Inc.; Koneksa, Altoida Inc.; Amgen Inc., Biogen Inc.; Empatica Inc.; Vivo Sense, IXICO plc, Adherium Limited, Neurotrack Technologies, Inc.; Aural Analytic; Huma; Sonde Health, Inc., and others, are attempting to increase market demand by investing in the research and development operations.

Vivoryan Therapeutics is a biopharmaceutical company focused on developing small-molecule drugs for the treatment of neurodegenerative diseases, including Alzheimer's disease. The company's primary focus is on developing drugs that target specific enzymes involved in neuroinflammation and protein misfolding, which are common characteristics of neurogenerative disorders. In March 2020, Vivoryon Therapeutics, a clinical-stage biotechnology company developing innovative therapies for Alzheimer’s disease, partnered with Winterlight Labs, a digital biomarker company specializing in voice analysis, to develop and validate a speech-based biomarker for Alzheimer's disease. The biomarker will be used in Vivoyon’s upcoming Phase 2b clinical trial of PQ912, a novel drug candidate for Alzheimer’s disease.

Medtronic is a multinational medical technology company headquartered in Dublin, Ireland, with its operational headquartered in the USA. Founded in the year 1949, it is one of the largest and most well-known companies in the medical device and healthcare industry. The company mainly emphasizing on developing and manufacturing a broad range of medical devices and technologies. These devices are used in various medical specialties, including cardiology, neurology, diabetes management, spinal surgery and more. In January 2023, Medtronic partnered with Evidation Health, a digital health company that develops digital biomarkers for a variety of diseases, to develop digital biomarkers for chronic diseases such as diabetes, heart disease, and Parkinson’s disease. The partnership will leverage Medtronic’s medical devices and Evidation Health’s digital biomarker platform to develop new digital biomarkers that can be utilized to improve the care of patients with chronic diseases.

Key Companies in the Digital Biomarkers market include

• ActiGraph LLC


• AliveCor Inc.


• Koneksa


• Altoida Inc.


• Amgen Inc.


• Biogen Inc.


• Empatica Inc.


• Vivo Sense


• IXICO plc


• Adherium Limited


• Neurotrack Technologies, Inc.


• Aural Analytic


• Huma


• Sonde Health, Inc.

Digital Biomarkers Industry Developments

February 2023:Verily, a life sciences research and development company owned by Alphabet Inc., partnered with AliveCor, a digital health company that develops AI-powered heart monitoring devices to develop and validate digital biomarkers for heart disease. The partnership will leverage AliveCor's KardiaMobile ECG device and Verily’s research expertise to develop new digital biomarkers that can be utilized to diagnose, monitor, and treat heart disease.

March 2022:Cognivue announced a partnership with Otsuka Pharmaceutical to develop and commercialize digital biomarkers for the early detection and monitoring of Alzheimer's disease.

April 2021:Medable, a leading provider of cloud-based digital platforms for the life sciences industry, partnered with Aural Analytics, a digital biomarker company specializing in speech analysis, to assess remote capture of speech patterns in cancer patients to monitor for patient deterioration and well-being.

Digital Biomarkers Market Segmentation

Digital Biomarkers Type Outlook

• Wearable


• Mobile Based Applications


• Sensors


• Others

Digital Biomarker Clinical Practice Outlook

• Diagnostic Digital Biomarkers


• Monitoring Digital Biomarkers


• Predictive and Prognostic Digital Biomarkers


• Others

Digital Biomarkers End-Use Outlook

• Healthcare Companies


• Healthcare Providers


• Payers


• Others

Digital Biomarkers Regional Outlook

• 
  North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• 
  Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• 
  Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• 
  Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America